Results

Publications

The need for COVID-19 clinical trials in LMICs

Abstract

Since the outbreak of the COVID-19 pandemic, the disease has spread worldwide with more than 603 million confirmed cases and with a death toll surpassing 648 million as of 6 September, 2022.1 Now in its third year, the pandemic is far from finished as the virus continues to claim victims and seize lives. Despite vaccine development and success, potential emergence of SARS-CoV-2 vaccine-resistant variants as well as waning of vaccine-induced immunity, may compromise the impact of vaccines and thus necessitate the need for therapeutics that can control the disease and save lives alongside vaccines

Journal/Conference Information

Frontiers in Public Health ,DOI: 10.3389/fpubh.2022.1038840, ISSN: https://pubmed.ncbi.nlm.nih.gov/36699935/, Volume: 10, Issue: 1, Pages Range: 10-12,